RxDoctor Payments DataLook up a doctor →

Anthony Olofintuyi, MD

Internal Medicine · Columbus, GANPI 1144384827

Payments from drug & device makers

$1,192,649in general payments, 2019–2025

Across 709 payments — averaging $1682.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertex$394K
  • Eli Lilly$287K
  • Alnylam Pharmaceuticals Inc.$262K
  • GSK$72K
  • Amgen$70K
  • Currax Pharmaceuticals LLC$51K
  • plus $56K from 10 others
$19,755in research payments, 2019–2025

Across 22 payments — averaging $897.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$17K
  • GSK$3K

What the payments were for

  • Travel & lodging$3,26073%
  • Food & beverage$1,11725%
  • Gifts$591%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,192,649 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$13,246
Medicare patients
20
Services billed
155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide115$119,652
Trelegy ElliptaFluticasone/Umeclidin/Vilanter71$48,124
EliquisApixaban69$39,705
RybelsusSemaglutide29$35,955
Tresiba Flextouch U-200Insulin Degludec47$35,651
LinzessLinaclotide60$33,112
Breztri AerosphereBudesonide/Glycopyr/Formoterol45$28,868
EntrestoSacubitril/Valsartan30$26,085
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen779$16,302
Xultophy 100-3.6Insulin Degludec/Liraglutide14$16,217
JanuviaSitagliptin Phosphate19$15,275
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog21$9,392
JanumetSitagliptin Phos/Metformin Hcl14$7,708
Lantus SolostarInsulin Glargine,hum.Rec.Anlog56$7,189
XareltoRivaroxaban11$6,305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6$23$171,823158 claims
GSKTrelegy Ellipta$72,082$48,12471 claims
PfizerEliquis$11$39,70569 claims
AstraZenecaBreztri Aerosphere$310$28,86845 claims
NovartisEntresto$54$26,08530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →